An oncology treatment company, Novocure, which treats tumours using electrical fields, has announced positive results from their STELLAR Trial phase 2 pilot scheme.
The trial is being used to assess the efficiency and safety of electrical field treatments when used in combination with standard cancer care, including chemotherapy. The trial looked at 80 mesothelioma cancer patients who have been diagnosed with the malignant cancer, which is caused by exposure to asbestos.
Following an interim analysis of 42 patients, they found that the one-year survival rate of patients who had electrical field treatments combined with chemotherapy and other standard treatments was 80%. This is in comparison to a 50% rate when patients just had standard treatments alone.
In addition, the median time in which patients survived without their disease progressing for the trial group was just over 7 months, in contrast to 5.7 months for those not included with this treatment.
The Company argue that the top-line results from their trial have shown clear improvement – they have not only increased the survival rate in patients but have also limited the tumour’s progression.
As yet no adverse events have been reported which has led for the Company pursuing FDA approval. Whilst seeking approval it is important to note that the Company’s data is still subject to further analysis. However, from these results alone the study appears to be positive.
What is mesothelioma?
Malignant mesothelioma is caused by asbestos exposure, and is a cancerous tumour that affects up to 3,000 Americans every year. Notably, this asbestos tumour gives patients a very poor prognosis. In fact, most studies suggest an average survival time of 12 months.
How can we help?
If you require assistance in pursuing an asbestos compensation claim for mesothelioma or other asbestos disease then please contact us today on our freephone number 0800 038 6767. Alternatively, head over to the ‘Contact Us’ page, complete the form and we will be in touch.